Summary

Viral Vectors-Based Gene Therapy for Non-Human Primates Market – Scope of Report
TMR’s report on the global viral vectors-based gene therapy for non-human primates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global viral vectors-based gene therapy for non-human primates market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global viral vectors-based gene therapy for non-human primates market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the viral vectors-based gene therapy for non-human primates market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global viral vectors-based gene therapy for non-human primates market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global viral vectors-based gene therapy for non-human primates market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global viral vectors-based gene therapy for non-human primates market.

The report delves into the competitive landscape of the global viral vectors-based gene therapy for non-human primates market. Key players operating in the global viral vectors-based gene therapy for non-human primates market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global viral vectors-based gene therapy for non-human primates market profiled in this report.

Key Questions Answered in Global viral vectors-based gene therapy for non-human primates Market Report
• What is the sales/revenue generated by viral vectors-based gene therapy for non-human primates across all regions during the forecast period?
• What are the opportunities in the global viral vectors-based gene therapy for non-human primates market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Viral Vectors-Based Gene Therapy for Non-Human Primates Market – Research Objectives and Research Approach
The comprehensive report on the global viral vectors-based gene therapy for non-human primates market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global viral vectors-based gene therapy for non-human primates market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global viral vectors-based gene therapy for non-human primates market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Viral Vectors-based Gene Therapy for Non-human Primates Market
4. Market Overview
4.1. Introduction
4.1.1. Vector Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Recent Advancements in Viral Vectors Technology
5.2. List of Leading CROs offering Non-human Primates based Preclinical Testing Services
5.3. PORTER’s Analysis on Viral Vectors for Non-human Primates Industry
5.4. Key Shortlisting Metrics for End-users
5.5. Regional Distribution of Non-human Primate Preclinical Studies
5.6. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
5.7. Impact of COVID-19 Pandemic on Viral Vectors for Non-human Primates Industry
6. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Vector Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Vector Type, 2020-2034
6.3.1. Adenoviral Vectors
6.3.2. Adeno-associated Vectors
6.3.3. Retroviral Vectors
6.3.4. Lentiviral Vectors
6.3.5. Other Vectors
6.4. Market Attractiveness By Vector Type
7. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Type of Non-human Primate
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
7.3.1. Marmosets
7.3.2. Rhesus Macaques
7.3.3. Cynomolgus Monkey
7.3.4. Others
7.4. Market Attractiveness By Type of Non-human Primate
8. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Technology, 2020-2034
8.3.1. Genetic Disorders
8.3.2. Infectious Diseases
8.3.3. Oncological Disorders
8.3.4. Neurodegenerative Disorders
8.3.5. Other Disorders
8.4. Market Attractiveness By Technology
9. Global Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Vector Type, 2020-2034
10.2.1. Adenoviral Vectors
10.2.2. Adeno-associated Vectors
10.2.3. Retroviral Vectors
10.2.4. Lentiviral Vectors
10.2.5. Other Vectors
10.3. Market Value Forecast By Type of Non-human Primate , 2020-2034
10.3.1. Marmosets
10.3.2. Rhesus Macaques
10.3.3. Cynomolgus Monkey
10.3.4. Others
10.4. Market Value Forecast By Technology, 2020-2034
10.4.1. Genetic Disorders
10.4.2. Infectious Diseases
10.4.3. Oncological Disorders
10.4.4. Neurodegenerative Disorders
10.4.5. Other Disorders
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Vector Type
10.6.2. By Type of Non-human Primate
10.6.3. By Technology
10.6.4. By Country
11. Europe Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Vector Type, 2020-2034
11.2.1. Adenoviral Vectors
11.2.2. Adeno-associated Vectors
11.2.3. Retroviral Vectors
11.2.4. Lentiviral Vectors
11.2.5. Other Vectors
11.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
11.3.1. Marmosets
11.3.2. Rhesus Macaques
11.3.3. Cynomolgus Monkey
11.3.4. Others
11.4. Market Value Forecast By Technology, 2020-2034
11.4.1. Genetic Disorders
11.4.2. Infectious Diseases
11.4.3. Oncological Disorders
11.4.4. Neurodegenerative Disorders
11.4.5. Other Disorders
11.5. Market Value Forecast By Country, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Vector Type
11.6.2. By Type of Non-human Primate
11.6.3. By Technology
11.6.4. By Country
12. Asia Pacific Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Vector Type, 2020-2034
12.2.1. Adenoviral Vectors
12.2.2. Adeno-associated Vectors
12.2.3. Retroviral Vectors
12.2.4. Lentiviral Vectors
12.2.5. Other Vectors
12.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
12.3.1. Marmosets
12.3.2. Rhesus Macaques
12.3.3. Cynomolgus Monkey
12.3.4. Others
12.4. Market Value Forecast By Technology, 2020-2034
12.4.1. Genetic Disorders
12.4.2. Infectious Diseases
12.4.3. Oncological Disorders
12.4.4. Neurodegenerative Disorders
12.4.5. Other Disorders
12.5. Market Value Forecast By Country, 2020-2034
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Vector Type
12.6.2. By Type of Non-human Primate
12.6.3. By Technology
12.6.4. By Country
13. Latin America Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Vector Type, 2020-2034
13.2.1. Adenoviral Vectors
13.2.2. Adeno-associated Vectors
13.2.3. Retroviral Vectors
13.2.4. Lentiviral Vectors
13.2.5. Other Vectors
13.3. Market Value Forecast By Type of Non-human Primate , 2020-2034
13.3.1. Marmosets
13.3.2. Rhesus Macaques
13.3.3. Cynomolgus Monkey
13.3.4. Others
13.4. Market Value Forecast By Technology, 2020-2034
13.4.1. Genetic Disorders
13.4.2. Infectious Diseases
13.4.3. Oncological Disorders
13.4.4. Neurodegenerative Disorders
13.4.5. Other Disorders
13.5. Market Value Forecast By Country, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Vector Type
13.6.2. By Type of Non-human Primate
13.6.3. By Technology
13.6.4. By Country
14. Middle East & Africa Viral Vectors-based Gene Therapy for Non-human Primates Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Vector Type, 2020-2034
14.2.1. Adenoviral Vectors
14.2.2. Adeno-associated Vectors
14.2.3. Retroviral Vectors
14.2.4. Lentiviral Vectors
14.2.5. Other Vectors
14.3. Market Value Forecast By Type of Non-human Primate, 2020-2034
14.3.1. Marmosets
14.3.2. Rhesus Macaques
14.3.3. Cynomolgus Monkey
14.3.4. Others
14.4. Market Value Forecast By Technology, 2020-2034
14.4.1. Genetic Disorders
14.4.2. Infectious Diseases
14.4.3. Oncological Disorders
14.4.4. Neurodegenerative Disorders
14.4.5. Other Disorders
14.5. Market Value Forecast By Country, 2020-2034
14.5.1. GCC
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Vector Type
14.6.2. By Type of Non-human Primate
14.6.3. By Technology
14.6.4. By Country
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. CRISPR Therapeutics AG
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Voyager Therapeutics, Inc.
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. Sarepta Therapeutics, Inc.
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. Neuracle Genetics
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Beacon Therapeutics
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. REGENXBIO Inc.
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. 4D Molecular Therapeutics
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
15.2.8. Rocket Pharmaceuticals, Inc.
15.2.8.1. Company Overview
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Business Strategies
15.2.8.5. Recent Developments